key: cord-0881815-2vcpspjb authors: Ji, H.-L. J.; Su, Z.; Zhao, R.; Komissarov, A. A.; Yi, G.; Liu, S.-L.; Idell, S.; Matthay, M. A. title: Insufficient hyperfibrinolysis in COVID-19: a systematic review of thrombolysis based on meta-analysis and meta-regression date: 2020-09-09 journal: medRxiv : the preprint server for health sciences DOI: 10.1101/2020.09.07.20190165 sha: 26a8b285626fb0b4b3d6fc6c9c68d3ff5d215ce0 doc_id: 881815 cord_uid: 2vcpspjb Background How aberrant fibrinolysis influences the clinical progression of COVID-19 presents a clinicopathological dilemma challenging intensivists. To investigate whether abnormal fibrinolysis is a culprit or protector or both, we associated elevated plasma D-dimer with clinical variables to identify a panoramic view of the derangements of fibrinolysis that contribute to the pathogenesis of COVID-19 based on studies available in the literature. Methods We performed this systematic review based on both meta-analysis and meta-regression to compute the correlation of D-dimer at admission with clinical features of COVID-19 patients in retrospective studies or case series. We searched the databases until Aug 18, 2020, with no limitations by language. The first hits were screened, data extracted, and analyzed in duplicate. We did the random-effects meta-analyses and meta-regressions (both univariate and multivariate). D-dimer associated clinical variables and potential mechanisms were schematically reasoned and graphed. Findings Our search identified 42 observational, or retrospective, or case series from six countries (n=14,862 patients) with all races and ages from 1 to 98-year-old. The weighted mean difference of D-dimer was 0.97 g/mL (95% CI 0.65, 1.29) between relatively mild (or healthy control) and severely affected groups with significant publication bias. Univariate meta-regression identified 58 of 106 clinical variables were associated with plasma D-dimer levels, including 3 demographics, 5 comorbidies, 22 laboratory tests, 18 organ injury biomarkers, 8 severe complications, and 2 outcomes (discharge and death). Of these, 11 readouts were negatively associated with the level of plasma D-dimer. Further, age and gender were confounding factors for the identified D-dimer associated variables. There were 22 variables independently correlated with the D-dimer level, including respiratory rate, dyspnea plasma K+, glucose, SpO2, BUN, bilirubin, ALT, AST, systolic blood pressure, and CK. We thus propose that "insufficient hyperfibrinolysis (fibrinolysis is accelerated but unable to prevent adverse clinical impact for clinical deterioration COVID-19)" as a peculiar mechanism. Interpretation The findings of this meta-analysis- and meta-regression-based systematic review supports elevated D-dimer as an independent predictor for mortality and severe complications. D-dimer-associated clinical variables draw a landscape integrating the aggregate effects of systemically suppressive and locally (i.e., in the lung) hyperactive derangements of fibrinolysis. D-dimer and associated clinical biomarkers and conceptually parameters could be combined for risk stratification, potentially for tracking thrombolytic therapy or alternative interventions. Introduction covariate, respectively ( Table 2) . Age-affected 18 variables include comorbidity, hypertension, diabetes, lymphocyte, CD4 + and CD8 + T cells, IL8, TNFα, eGFR, hemoglobin, albumin, CK-MB, onset to admission, onset to PCR negative, discharged, secondary infection, acute kidney injury, and acute liver injury. There were 10 variables confounded by both age and male, including diastolic pressure, chronic lung diseases, WBC, IL2R, IL6, ESR, GGT, CURB 65 score, coagulopathy, and DIC. These four variables were markedly affected by covariate male: platelets, fibrinogen, alkaline phosphatase, and onset to dyspnea. Finally, 22 variables were significantly associated with D-dimer: respiratory rate, systolic pressure, dyspnea, serum K + , neutrophils, globulin, CRP, ferritin, LDH, PCT, SpO 2 , blood glucose, BUN, total bilirubin, ALT, AST, CK, mortality, ventilation, ARDS, sepsis, and acute cardiac injury (Figure 3 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20190165 doi: medRxiv preprint We aimed to systematically analyze the relationships between circulating D-dimer level in the blood and clinical variables to explore the underlying mechanisms for the dysfunctional fibrinolysis in critically ill COVID-19 patients. A considerable range of plasma D-dimer levels on admission for severely affected patients exists. The directions of dynamically changed FDPs for hospitalized patients are different between discharged and deceased cohorts. As revealed by our meta-regression analysis, plasma D-dimer is associated with comorbidities, demographics, some laboratory tests, radiology, hospitalization, complications, and outcomes. These results suggest that in addition to serving as an independent predictor for fatality, severity, and a feasible marker for daily monitoring thrombolytic therapy, D-dimer is a non-specific biomarker that interacts with other coagulation molecules, inflammatory cytokines, and markers for organ/tissue injury. Of note, the interplay of acute-phase proteins with fibrinogen and D-dimer suggests that infectioninduced inflammation (cytokines and chemokines) initiates a "hyperfibrinolysis". This notion is supported by the disassociation of D-dimer with the entire coagulation panel (PT, APTT, factor VIII and XI, TAT, etc.) 52, 53 . In general, a relatively hyperfibrinolytic homeostasis maintains vascular patency and normal organ function under physiological conditions ( Figure 3B ). SARS-CoV-2 and co-bacterial infection develops a hypercoagulable state followed by hyperfibrinolysis in COVID-19. If hyperfibrinolysis can counter excessive coagulopathy, then the patients will be protected against thrombosis. Otherwise, insufficient local hyperfibrinolysis in the lung of non-survivors will be exhausted and appears as "systemic shutdown". 1. Clinicopathological mechanisms of fibrinolysis in COVID-19. Soluble fibrinogen is synthesized in the liver (1.7-5g/d) primarily and others, including the bone marrow, brain, lung, and gastrointestinal epithelium ( Figure 4A ). It mainly distributes in the plasma (75%), interstitial fluid (16%), platelets, and lymph 54, 55 . IL6 and other proinflammatory cytokines/chemokines, steroids, and miRNAs upregulate the fibrinogen synthesis up to 10-fold during the acute phase of injury and infection. Fibrinogen (2-3%) can be turned over to fibrin monomers by thrombin and cleaved by plasmin, the process termed fibrinogenolysis 54, 56 . Fibrinogen degradation products (FgDP) are 2-or 3-fold that of D-dimer but with a shorter half lifetime (2.8 h vs 16 h for D-dimer). Crosslinked fibrin is formed in the presence of FXIIIa. At the endothelial cell surface of injured blood vessels, fibrin(ogen) "glues" the plugs formed by the aggregation of platelets to develop thrombi (clots). Excessive fibrin deposition and inflammation activate endothelial cells to produce tPA and urokinase plasminogen activator (uPA) 54, 55 . Either tPA or uPA is capable of cleaving hepatocyte-derived plasminogen to activate plasmin. Plasmin proteolytically cleaves fibrin within the thrombi into FDP and D-dimers, the end products of fibrinolysis. Given the very short half lifetime (in seconds or minutes) of endogenous thrombin, tPA, uPA, and plasmin, and the overwhelming antithrombin, plasminogen activator inhibitor 1 (PAI-1), and plasmin inhibitors with a much longer lifetime in the plasma 57 , the primary cleavage of plasminogen and fibrin may predominately take place at the surface of clots. Eventually, FgDP and FDP (D-dimer) will be catabolized in the liver and captured by the reticuloendothelial system and excreted to the bile 54, 55 . Another clearance pathway is via the kidney to excreted to urine 54, 55 . D-dimer assay has routinely applied for excluding PE, deep venous thromboembolism, and DIC, as well as a marker for monitoring the effects of fibrinolytic/thrombolytic therapy. Age is associated with an increased D-dimer level in COVID-19 patients at admission as a covariate or independent prognostic marker for the outcomes of COVID-19. The cutoff value of D-dimer (0.5 μg/mL) is age-dependent for healthy cohorts 58, 59 . Our subgroup analysis is consistent with the concept that adults older than 50 approach the threshold of the Ddimer levels seen in normalcy ( Table S9) . The difference in D-dimer between men and women is minor in healthy population 59 . The positive association of D-dimer with the percentage of male patients in COVID studies indicates more severe cases in men than women when admitted. Mechanisms for increased baseline D-dimer at admission: We demonstrate that patients with comorbidity, including total comorbidity, hypertension, diabetes, and chronic respiratory diseases, correlates with D-dimer levels at admission. The association can be explained by the comorbidity-associated elevations in plasmin 60 . Increased D-dimer has been reported in the following conditions 56, 59, 61 : DIC, VTE, pregnancy, advance age, malignancy, sepsis, burns, trauma, myocardial injury, cerebrovascular event, liver disease, severe renal disease, surgery, ARDS, pancreatitis, diabetes, Alzheimer, disability, and neonatal period. The different time points for admission and D-dimer testing could partially account for the different D-dimer levels between groups and studies. This is in fact the rationale of this work to apply meta-regression analyses. Patients with severe COVID-19 may be those who were ill for a longer period than mild controls. This is supported by the association of the D-dimer level and the days from onset to admission ( Table 2) . Alternatively, the progression of disease may be much quicker in critically ill patients at admission. A significant increase in plasma tPA was reported in ICU patients with elevated D-dimer 62, 63 . In contrast, the α2-antiplasmin protein was at the upper limit of normal level 62 . Synthesis, metabolism, distribution, and excretion of fibrin(ogen). Our regression analysis reveals that elevated Ddimer is associated with a broad spectrum of immune responses to SARS-CoV-2 infection, including increased pro-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20190165 doi: medRxiv preprint inflammatory cytokines (IL2R, IL6, IL8, and TNFα), acute phase proteins (CRP/C-reactive protein, fibrinogen, ferritin, and albumin), and inflammation indicators (ESR-erythrocyte sedimentation rate, PCT-procalcitonin, globulin, white blood cells, neutrophil, lymphocyte, and CD4 + & CD8 + T cells). Moreover, the days for reversion of the PCR test to negative is related to the D-dimer level. These correlations support the concept that interactions between high levels of circulating cytokines and hyperfibrinolysis are functionally correlated. The binding of the spike proteins of SARS-CoV-2 to the ACE2 receptor in host respiratory epithelial cells downregulates the protective ACE2/Ang1-7/Mas axis, leading to increased expression of PAI-1 64 . Airway and lung epitheliitis releases proinflammatory cytokines to attract leukocytes from the blood. Moreover, infiltrated immune cells are activated and unleashed to attach normal lung tissues by releasing overwhelming cytokines. These cytokines upregulate positive acute-phase protein (i.e., fibrinogen), TF, and trypsin expression and inhibit negative proteins (i.e., albumin). Trypsin-activated matrix metalloproteinases break down the basolateral membrane and interstitial extracellular matrix. Further, endotheliopathy occurs in infected capillaries to initiate a local hypercoagulable state. The kinin-bradykinin is activated by IL6 to stimulate tPA expression in endothelial cells 64 . Deposition of fibrin (clotting) activates endothelial cells to express more IL8, which suppresses clot lysis time 65 . This, combined with the hypoxia-causing eryptosis, may be the reason for IL8 associating with high mortality in influenza patients. ESR is associated with the severity of COVID-19 patients 66 . In addition to carrying oxygen, erythrocyte-bound streptokinase and tPA break down the clots. Extrathyroidal produced PCT if maintained at an inflated level by cytokines is an indicator of poor outcomes of COVID-19. It has been used as a marker for co-bacterial infection in septic shock and influenza. Neutrophil extracellular traps (NETs) may contribute to organ damage and promote thrombosis and fibrinolysis via elastase, so do lymphocytes/macrophages. Hepatocyte-synthesized globulins and albumin are involved in liver function, coagulation, and antiinflammation. Their reduced levels by vast consumption predict a poor outcome. Albumin acts as anticoagulant and antiplatelets and increases vascular permeability 67 , which explains the links between elevated Ddimer and hypoalbuminemia ( Figure 4B ). Coagulation and fibrinolysis. Our results show a close relation between the plasma D-dimer and thrombocytopenia, hyperfibrinogenemia, and thrombosis. Significant reduction in platelets could be due to 1) vast consumption for adhesion and aggregation to the surface of injured lung capillaries, 2) a decrease in platelet release from fully mature megakaryocytes in the injured lung, and 3) abnormal hematopoiesis of infected bone marrow. Hypercoagulation and abnormal fibrinolysis are inconsistent in COVID-19 patients. There is no correlation between abnormal coagulation variables and thrombosis except elevated D-dimer 53 . The hypercoagulable state is systemic, but the hyperfibrinolysis occurs in the pulmonary capillaries. This is supported by the "fibrinolysis resistance" or "fibrinolysis shutdown" in vitro whole blood clot lysis 22, 68, 69 . The moderate reduction in circulating plasminogen of ICU COVID-19 patients eliminates the thrombolytic effects of tPA 70 , which is supported by thromboelastometry (TEM) 49, 71 . The half lifetime of plasminogen is 2.2 days, the fibrinolysis resistance in vitro cannot be explained by the distance to the clots in vivo (about 45 seconds per cycle through the circulation system) and the time between collecting blood to assay. Indeed, sequential TEM tests on days 0, 5, and 10 found no fibrinolytic activity too 71 , probably due to extremely elevated PAI-1 and insufficient supply of tPA. Another line of evidence is the dynamic changes in increased TAT (thrombin-antithrombin) and reduced PAP (plasmin-antiplasmin) complexes in non-survivors 72 , a sign of hyperactive plasminogen cleavage and resultant hyperfibrinolysis. This is also probably due to the adhesion of plasminogen to the clot at the cell surface and/or unable circulating through the pulmonary capillaries blocked by microthrombi. Thrombin level was significantly reduced in COVID-19 patients associated with increased D-dimer 62 . Of note, spontaneous fibrinolysis was enhanced by high tPA plasma of a subset COVID-19 patients 63 . Cell/tissue injury. Lysis of platelets, erythrocytes, and other cells caused by infection contribute to higher serum K + levels and reduced hemoglobin. The tissue damage is supported by the increased LDH level, together with serum K + and hemoglobin correlate with D-dimer. A decrease in renal excretion of K + salt may worsen the hyperkalemia in COVID-19. Cell death at the clotting site and alveoli increase the release of fibrin(ogen) into the blood and the risk of embolism. Meanwhile, a new reaction surface is exposed for producing D-dimer by plasmin both locally and systemically. Acute lung injury. D-dimer is associated with acute lung injury/ARDS, including hypoxia (respiratory rate, dyspnea, SpO 2 , CURB 65, and onset to dyspnea) and the need for mechanical support. The lung is a key early target organ of SARS-CoV-2 infection and the crucial source of D-dimer. At the early stage before vascular endothelialitis, extravascular fibrin degradation in the alveolar sacs and interstitium could be the major site responsible for the generation of elevated D-dimer levels. uPA in the exudate cleaves plasminogen to generate plasmin, together with elastases released from macrophage and neutrophils to resolve fibrin, but the process is greatly inhibited by locally increased levels of PAI-1 in most forms of ARDS [73] [74] [75] and likely in that induced by COVID-19. Both fibrin and FDPs will be retained to the venous system via the lymphatic system (17L/day). The lymphatic retention may take place in other edematous organs until the patients are either recovered or expired 76, 77 . This may be the case for patients with elevated D-dimer but not vascular thromboembolism. Disassociations of increased plasma D-dimer with either augmented tPA or PAI-1 in relatively young 9 COVID-19 patients (age 41.7 ± 14) supports the importance of extravascular fibrinolysis 63 . This is strongly supported by the benefits of inhaled fibrinolytics [78] [79] [80] , postmortem findings [15] [16] [17] [18] [19] , and clinical features. Vasculopathy in the pulmonary capillaries further enhances the local hyperfibrinolytic process. Plasma D-dimer and other FDPs rise along with the pulmonary hypercoagulable state and a proinflammatory state. Hypoxia occurs in patients with the DAD lungs and promotes fibrin deposition and degradation. Mechanical ventilation with positive pressure could facilitates the retention of extravascular generated D-dimers. Acute liver injury. Our results show an association of acute liver injury and elevated D-dimer in the blood. Postmortem biopsies detected congestion, vascular changes, and periportal lymphocyte infiltration and fibrosis 15, 17, 18 . The D-dimer level is increased in various liver diseases, as the result of the overwhelming deposition of fibrin(ogen) and subsequent inflammation injury in the liver, which leading to suppressed catabolism of D-dimer. Acute kidney injury. The association of D-dimer and estimated glomerular rate (eGFR) in COVID-19 patients is supported by the clinical practice for adjusting D-dimer cutoff value for patients with renal dysfunction 81 . Reduced eGFR will reduce the renal clearance of D-dimer and result in an elevated plasma D-dimer level 82 . On the other hand, increased blood urea nitrogen (BUN) level (cutoff: >4.6 mmol/L) as well as D-dimer (cutoff: ≥0.845 μg/mL) serves as an independent risk factor for predicting in-hospital mortality 83 . Coronavirus-like particles were detected in damaged kidneys 19, 84 and assumably stimulating renal uPA synthesis. Acute cardiac injury. The heart per se appears not a significant target of SARS-CoV-2 infection, although ACE2 receptors are expressed in myocytes. This could be due to sufficient blood supply to dwindle local inflammation and hypercoagulation effectively. Some patients showed lymphocytic myocarditis and myositis 19, 85 . Approximately 20% of postmortem samples had fibrin thrombi and interstitial edema 85 . Thus, hypoxic myocardial diseases, including heart stroke, myocardial infarction caused by infection, resulting in an increment in plasma D-dimer 86 . The acute cardiac injury was detected by elevated CK, CK-MB, and myoglobin. Of note, a 16-year LIPID trial demonstrates that higher D-dimer is an independent predictor of all-cause mortality, cardiovascular mortality, cancer mortality, and other fatal events 87 . Hyperglycemia. Nearly half of COVID-19 patients (47%) had elevated levels of blood glucose at admission 88 . Hyperglycemia is an independent risk factor for progression to critical cases and in-hospital deaths for both mild and severe patients. Intriguingly, stress hyperglycemia is an independent risk factor associated with worse outcomes among critically ill patients 89 . SARS-CoV-2 induced cytokine storm, and the direct infection of the pancreas leads to insulin resistance. Hyperglycemia then results in increased TF, FVII, thrombin and PAI-1 levels, promoting clot formation and restraining fibrinolysis. Glycation and oxidation of these coagulation and fibrinolysis proteins in compact clots develops resistance to plasmin 90 . Systemic complications. Systemic complications, including bacterial co-infection, septic shock, DIC, and thromboembolic events in large blood vessels, have high incidences and poor outcomes in non-survivors. D-dimer is associated with these severe complications in critically ill patients. All of the mechanisms illustrated in Figure 4B are involved in the hyperfibrinolysis at the late stage. The effects of tPA delivery are poor for multiorgan failures, as we reviewed below. A sudden increment in the D-dimer level in ICU patients. A rapid rise in D-dimer level was described in non-survivors, particularly for the last test before death. It can be caused by the rapid exacerbation of septic organ failures, DIC, and secondary infection. Pump head thrombosis in patients treated with ECMO 28 , ventilation 14, 91 , steroids, tocilizumab, and tPA administration leads to a transient augmentation in plasma D-dimer 12 . Our results showed a strong positive association of elevated D-dimer on admission and mortality, indicating the prognostic value of an elevated D-dimer for the high risk of death. This is further corroborated by the positive correlation between D-dimer and days from onset to admission, the need for ventilation, and the days taken for PCR test reversion to negative. Another line of supportive evidence is the negative relation of D-dimer and discharged probability. For the first time, our data show that prompt admission and clearance of SARS-CoV-2 virus may alleviate the severity and reduce the fatal events by preventing the hyperfibrinolysis and inflammation. D-dimer, as an independent prognostic marker, is supported by other reviews [92] [93] [94] [95] and clinical studies 47, 96 . However, given the dynamic feature of plasma D-dimer, the peak D-dimer value improves the prognostic relevance [97] [98] [99] [100] [101] . Combination with other clinical parameters of biomarkers, for example, IL6 or chest images, is recommended for the diagnosis and follow-up of PE and VTE because D-dimer could be raised by extravascular fibrinolysis 76 . 3. Strengths. For the first time, we have systematically reviewed the clinicopathologic mechanisms of fibrinolysis with elevated D-dimer and its diagnostic and prognostic relevance. Based on the findings, we infer that this test may be tractable for the stratification and interventions of COVID-19 patients. The associations of D-dimer and other clinical variables indicate either a relationship, which may be cause-effect or indirect. The D-dimer-associated variables have been confirmed or could be prognostic biomarkers for developing fatal events and in-hospital mortality. Extremely elevated plasma D-dimer is the consequence of hyperfibrinolysis predominately in the pulmonary capillaries and other organs. A All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20190165 doi: medRxiv preprint dynamic increase in the D-dimer level may be associated with fatality and thromboembolism, while we infer that a continuous decline by daily testing will generally lead to recovery. 4. Limitations. Because COVID-19 is a new emerging disease, most of the included studies are descriptive, case series, retrospective, single-center, and observational. Few are randomized trials and perspective. Most of the studies included are from China/Asia, where the pandemic was initiated. Diversity in cohorts exists from children to seniors associated with variant comorbidities and complications. Inconsistent grouping strategies between studies pose a challenge for metaanalysis, for example, ICU vs non-ICU, ARDS vs non-ARDS, control vs COVID-19, survivor vs non-survivor, severe vs non-severe, VTE vs non-VTE, death vs recovered, mild vs moderate, moderate vs severe, normal vs abnormal D-dimer, etc. We cannot exclude the potential pre-and post-test deviations regarding the methodology for D-dimer assays. Metaregression but not meta-analysis may partially eliminate these deviations. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . HLJ, ZLS, and RZZ were responsible for searching the literature, reviewing extracted data, meta-analysing data, and initiating drafts of this manuscript. HLJ, RZZ, MAM, SI, SLL, GHY, and AK prepared the manuscript and all authors approved submission. None of the authors have any conflict of interest to declare. This study was supported by NIH grants HL87017, HL095435, HL134828, HL154103, HL130402, AI112381, AI150473, and HL14285301. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.07.20190165 doi: medRxiv preprint Random-effects meta-analysis of D-dimer level. A. Forest plot. We selected studies that had subgroups, which could be divided into relatively mild (including normal) and severe groups. We pooled weighted mean differences (WMD, black diamond, and gray square) and 95% CI (horizontal lines through the diamonds) of D-dimer from eligible 23 studies. Studies with only one group or moderate group were excluded. The red diamond represents the overall WMD. B. Egger's publication bias plot. N=89, P<0.001. C. Filled funnel plot. P<0.001. Circle, raw data; square, pseudo data needed for symmetric distribution. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . Table 2 . D-dimer associated clinical variables (58 of 106 in total with a sample size ≥ 5, P < 0.05) identified by univariate-regression. Abbreviations: CI, confidence interval. Obs, the number of groups from the included studies. WBC, white blood cells. CK, creatine kinase. CK-MB, creatine kinase myocardial band. ALT, alanine aminotransferase. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 9, 2020. . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Coagulopathy and antiphospholipid antibodies in patients with COVID-19 Development and external validation of a prognostic multivariable model on admission for hospitalized patients with Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebocontrolled, multicentre trial Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York city area ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the early stage of outbreak in Wuhan COVID-19 and kidney transplantation Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series Rescue fibrinolysis in suspected massive pulmonary embolism during SARS-CoV-2 pandemic Pulmonary embolism and increased levels of D-dimer in patients with coronavirus disease High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study COVID-19 and its implications for thrombosis and anticoagulation Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19 Postmortem examination of patients with COVID-19 Pathological findings of postmortem biopsies from lung, heart, and liver of 7 deceased COVID-19 patients Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series Thrombosis risk associated with COVID-19 infection. A scoping review COVID-19 related coagulopathy: a distinct entity? Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series Rescue therapy for severe COVID-19 associated acute respiratory distress syndrome (ARDS) with tissue plasminogen activator (tPA): a case series Early outcomes with utilization of tissue plasminogen activator in COVID-19 associated respiratory distress: a series of five cases Combination of thrombolytic and immunosuppressive therapy for coronavirus disease 2019: A case report COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis Thrombolysis restores perfusion in COVID 19 hypoxia Potential of heparin and nafamostat combination therapy for COVID-19 Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with COVID-19: a case series Anti-protease treatments targeting plasmin(ogen) and neutrophil elastase may be beneficial in fighting COVID-19 Large-vessel stroke as a presenting feature of COVID-19 in the young Clinical and immunological features of severe and moderate coronavirus disease 2019 Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study COVID-19 with different severities: a multicenter study of clinical features Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China Clinical characteristics of hospitalized COVID-19 patients in New York city The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome COVID-19 testing, hospital admission, and intensive care among 2,026,227 United States veterans aged 54-75 years Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up Clinical course and outcomes of 344 intensive care patients with COVID-19 Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China Clinical characteristics of imported cases of COVID-19 in Jiangsu province: a multicenter descriptive study Clinical characteristics and outcomes of cancer patients with COVID-19 Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 Analysis of coagulation parameters in patients with COVID-19 in Shanghai Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis Systematic review and meta-analysis of nasal potential difference in hypoxiainduced lung injury Serious adverse events of cell therapy for respiratory diseases: a systematic review and meta-analysis All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted COVID-19 coagulopathy: an in-depth analysis of the coagulation system Fibrin formation, structure and properties Studies of the metabolism and distribution of fibrinogen in healthy men with autologous 125-I-labeled fibrinogen D-dimer: preanalytical, analytical, postanalytical variables, and clinical applications Label-free kinetic studies of hemostasisrelated biomarkers including D-dimer using autologous serum transfusion D-dimer: an overview of hemostasis and fibrinolysis, assays, and clinical applications Age-and sex-dependent reference intervals for Ddimer: evidence for a marked increase by age Elevated plasmin(ogen) as a common risk factor for COVID-19 susceptibility The D-dimer assay Hypofibrinolytic state and high thrombin generation may play a major role in sars-cov2 associated thrombosis Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients Coronavirus Disease 2019: The Role of the Fibrinolytic System from Transmission to Organ Injury and Sequelae Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8 Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): a pooled analysis Hypoalbuminemia, coagulopathy, and vascular disease in COVID-19 Platelet drop and fibrinolytic shutdown in patients with sepsis Fibrinolysis resistance: a potential mechanism underlying COVID-19 coagulopathy Circulating Plasminogen Concentration at Admission in Patients with Coronavirus Disease 2019 (COVID-19) Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia Specific coagulation markers may provide more therapeutic targets in COVID-19 patients receiving prophylactic anticoagulant Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome Coagulation, fibrinolysis, and fibrin deposition in acute lung injury Update on acute lung injury and critical care medicine All those D-dimers in COVID-19 Re The source of elevated plasma D-dimer levels in COVID-19 infection Plasminogen improves lung lesions and hypoxemia in patients with COVID-19 Plasmin improves blood-gas barrier function in oedematous lungs by cleaving epithelial sodium channels Meta-analysis of preclinical studies of fibrinolytic therapy for acute lung injury Renal function-adjusted D-dimer levels in critically ill patients with suspected thromboembolism Effects of impaired renal function on levels and performance of D-dimer in patients with suspected pulmonary embolism Diagnostic performance of initial blood urea nitrogen combined with D-dimer levels for predicting in-hospital mortality in COVID-19 patients The clinical manifestations and management of COVID-19-related liver injury Pulmonary and systemic involvement of COVID-19 assessed by ultrasound-guided minimally invasive autopsy Predictive value of myoglobin and D-dimer on severe heat stroke: a clinical analysis of 38 patients with severe heat stroke D-dimer predicts long-term cause-specific mortality, cardiovascular events, and cancer in patients with stable coronary heart disease: LIPID study Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study Relative hyperglycemia is an independent determinant of in-hospital mortality in patients with critical illness Coagulation and fibrinolysis in diabetes Hematological features of persons with COVID-19 Elevated D-dimer levels are associated with increased risk of mortality in COVID-19: a systematic review and meta-analysis D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission D-Dimer serum levels as a biomarker associated for the lethality in patients with coronavirus disease 2019: a meta-analysis Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19 The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China Dynamic relationship between D-dimer and COVID-19 severity Time-dependent changes in the clinical characteristics and prognosis of hospitalized COVID-19 patients in Wuhan, China: A retrospective study Evaluation of variation in D-dimer levels among COVID-19 and bacterial pneumonia: a retrospective analysis Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study Clinical features of 85 fatal cases of COVID-19 from Wuhan. A retrospective observational study COVID19 coagulopathy in Caucasian patients Prominent changes in blood coagulation of patients with SARS-CoV-2 infection Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy A new coronavirus associated with human respiratory disease in China Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study